USPTO Examiner PYLA EVELYN Y - Art Unit 1633

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18926867STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREONOctober 2024March 2025Allow511YesNo
18591883STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREONFebruary 2024September 2024Allow711YesNo
18394522HARVESTING CELL-BASED MEATDecember 2023March 2024Allow310NoNo
18387555XENOTRANSPLANTATION PRODUCTS AND METHODSNovember 2023June 2025Allow1910NoNo
18470861Expanding Cells In A BioreactorSeptember 2023March 2025Allow1810NoNo
18239216INJECTABLE HYDROGEL FOR TREATMENT OF SEGMENTAL BONE DEFECTAugust 2023December 2024Allow1611NoNo
18351804WET PRESERVATION OF TISSUEJuly 2023April 2025Allow2120YesNo
183514883-DIMENSIONAL (3D) TISSUE-ENGINEERED MUSCLE FOR TISSUE RESTORATIONJuly 2023April 2025Allow2111NoNo
18306152MICROBEADS FOR CELL CULTURE AND METHOD OF MONITORING CELL CULTURE USING THE SAMEApril 2023May 2025Allow2510NoNo
18152470IN VITRO METHOD FOR CREATING A VIABLE CONNECTIVE TISSUE AND/OR OSSEOUS TISSUEJanuary 2023December 2024Allow2310NoNo
18076785NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLESDecember 2022September 2024Allow2210NoNo
177799913D scaffold comprising a biocompatible polymer with a colonization chamber open at the top for biological cells, and with a canal vessel surrounding the colonization chamberNovember 2022September 2024Allow2821YesNo
17971623Low-macrophage-adhesion/activation culture devices for continuous hematopoiesis and expansion of hematopoietic stem cells and progenitor cellsOctober 2022January 2025Abandon2710NoNo
18046678PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAMEOctober 2022December 2024Allow2710NoNo
17935334HARVESTING CELL-BASED MEATSeptember 2022December 2023Allow1521YesNo
17817051WET PRESERVATION OF TISSUEAugust 2022August 2024Allow2510NoNo
17870569METHOD FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELLSJuly 2022April 2025Allow3210NoNo
17850882CELL PREPARATION METHOD, CELL CULTIVATION DEVICE, AND KITJune 2022January 2025Abandon3110NoNo
17827934BIOENERGETIC BONEMay 2022May 2025Allow3520YesNo
17664194CELL CRYOPRESERVATION COMPOSITION AND CRYOPRESERVATION METHODMay 2022June 2024Allow2500NoNo
17736953PROCESSES FOR GENERATING TIL PRODUCTS ENRICHED FOR TUMOR ANTIGEN-SPECIFIC T-CELLSMay 2022March 2023Allow1110NoNo
17736579DEVICES AND METHODS FOR DELIVERING THERAPEUTICSMay 2022August 2024Allow2810YesNo
17723748Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5 and LGR6 Expressing Epithelial Stem CellsApril 2022November 2022Allow710NoNo
17641250METHODS FOR DERIVING AUTOLOGOUS AND HYPOIMMUNOGENIC HAIR FOLLICLE CONTAINING SHEETS IN VITROMarch 2022April 2025Abandon3701NoNo
17689251SCAFFOLD-FREE 3D BIOPRINTING OF PORCINE CELLSMarch 2022February 2025Abandon3511NoNo
17646539USE OF TERM AMNIOTIC FLUID CELLS FOR THE TREATMENT OF ACUTE AND CHRONIC RESPIRATORY DISEASESDecember 2021August 2022Allow711YesNo
17532509TISSUE PRODUCTS WITH ACTIVE AGENTS AND METHODS OF PRODUCTIONNovember 2021August 2024Abandon3310NoNo
17528822CARDIOSPHERE-DERIVED CELLS AND EXOSOMES SECRETED BY SUCH CELLS IN THE TREATMENT OF MUSCULAR DYSTROPHYNovember 2021June 2025Allow4220NoNo
17509260PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAMEOctober 2021April 2022Allow510NoNo
17503634APPARATUS AND METHOD FOR ESTABLISHMENT OF INDUCED PLURIPOTENT STEM CELLSOctober 2021September 2024Allow3520YesNo
17409466METHOD OF TREATMENTAugust 2021August 2024Abandon3610NoNo
17430648EXTRACELLULAR MATRIX-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME, AND THREE-DIMENSIONAL TISSUE CONSTRUCT AND METHOD FOR PRODUCING SAMEAugust 2021May 2025Abandon4511NoNo
17347077XENOTRANSPLANTATION PRODUCTS AND METHODSJune 2021July 2023Allow2510NoNo
17341206Silica Encapsulated DNA on Magnetic NanoparticlesJune 2021November 2024Allow4241YesNo
17298352HYDROGEL BIOMIMETIC FOR INVASIVE DISEASESMay 2021November 2024Abandon4101NoNo
17326734Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5 and LGR6 Expressing Epithelial Stem CellsMay 2021January 2022Allow810YesNo
17244437COMPOSITIONS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIZING ENTEROCOLITIS IN INFANTS AND YOUNG CHILDRENApril 2021March 2025Allow4640NoNo
17237336PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAMEApril 2021June 2021Allow200NoNo
17227217PERFUSION SYSTEM FOR HARVESTING BONE MARROWApril 2021March 2024Abandon3511NoNo
17185545MICROCAPILLARY NETWORK BASED SCAFFOLDFebruary 2021September 2024Abandon4330NoNo
17269479MEDICINE USING HSP47 INHIBITOR TO ENHANCE SENSITIVITY TO CHEMOTHERAPEUTIC AGENTFebruary 2021June 2025Abandon5220NoNo
17169765SYSTEM AND METHOD FOR CELL LEVITATION AND MONITORINGFebruary 2021April 2024Allow3821NoNo
17145877CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERYJanuary 2021December 2024Allow4720NoNo
17127281METHODS FOR STABILIZING A BIOPROSTHETIC TISSUE BY CHEMICAL MODIFICATION OF ANTIGENIC CARBOHYDRATESDecember 2020June 2024Allow4221NoNo
17114685METHODS FOR PRODUCTION OF HUMAN HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOFDecember 2020June 2024Allow4221NoNo
17087571CELL EXPANSIONNovember 2020October 2024Allow4811YesNo
17080128METHOD FOR MANUFACTURING STEM CELL HAVING APPROPRIATE SIZE FOR INTRAVASCULAR ADMINISTRATIONOctober 2020November 2023Abandon3720NoNo
17079821PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAMEOctober 2020February 2021Allow400NoNo
17079720REVERSIBLE STENCILS FOR FABRICATING MICRO-TISSUESOctober 2020September 2023Allow3510NoNo
17072625COATED BIOLOGICAL COMPOSITIONOctober 2020October 2024Allow4831YesNo
17071693BIOLOGIC COMPOSITION AND METHOD OF MANUFACTUREOctober 2020March 2023Allow2911NoNo
17065335PROGENITOR CELLS OF MESODERMAL LINEAGEOctober 2020October 2023Allow3711YesNo
17017002XENOTRANSPLANTATION PRODUCTS AND METHODSSeptember 2020December 2020Allow300NoNo
17016937XENOTRANSPLANTATION PRODUCTS AND METHODSSeptember 2020November 2020Allow200NoNo
17013165Engineered Tissues for in vitro Research Uses, Arrays Thereof, and Methods of Making the SameSeptember 2020March 2025Allow5421NoNo
16983190ACELLULAR BIOLOGIC COMPOSITION AND METHOD OF MANUFACTUREAugust 2020March 2024Allow4350YesNo
16939889WET PRESERVATION OF TISSUEJuly 2020July 2022Allow2441YesNo
16927390Lipofilling with ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling or for facial filling and/or rejuvenationJuly 2020August 2023Abandon3701NoNo
16960310PROCESSES FOR GENERATING TIL PRODUCTS ENRICHED FOR TUMOR ANTIGEN-SPECIFIC T-CELLSJuly 2020May 2024Allow4621NoNo
16911756METHOD FOR CULTURING BONE MARROW-DERIVED MESENCHYMAL STEM CELLSJune 2020September 2024Abandon5130NoNo
16772712IN VITRO METHOD FOR CREATING A VIABLE CONNECTIVE TISSUE AND/OR OSSEOUS TISSUEJune 2020October 2022Allow2811NoNo
16898224WET PRESERVATION OF TISSUEJune 2020April 2023Allow3451YesNo
16769800Products and Methods for Assessing and Increasing Klotho Protein LevelsJune 2020January 2024Abandon4421YesNo
16765495METHOD FOR AGGREGATING CELL MASS AND DEVICE FOR AGGREGATING CELL MASSMay 2020August 2024Allow5131YesNo
16861446ARTIFICIAL TISSUE COMPRISING ARTIFICIAL PAPILLARY LAYER, ARTIFICIAL SKIN AND METHOD OF MANUFACTURING SAMEApril 2020April 2023Abandon3621NoNo
16652099HIGHLY FLEXIBLE DEGRADABLE FIBERSMarch 2020February 2023Allow3521YesNo
16830213PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (N0N-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAMEMarch 2020November 2020Allow701NoNo
16649041THE METHOD OF OBTAINING PIGMENTED CELLS IN VITRO BY THE DIFFERENTIATION OF HUMAN INDUCED PLURIPOTENT STEM CELLSMarch 2020May 2023Allow3831YesNo
16823841PHENOTYPE PROFILE OF HUMAN RETINAL PROGENITOR CELLSMarch 2020December 2023Allow4541NoNo
16818839METHODS OF MAKING A WOUND TREATMENT COMPOSITIONMarch 2020January 2023Abandon3561YesYes
16804823ANGIOGENIC AGENT AND METHOD OF MANUFACTURING THE SAMEFebruary 2020June 2022Allow2820YesNo
16634377HUMAN ADIPOSE TISSUE PROGENITORS FOR AUTOLOGOUS CELL THERAPY FOR LIPODYSTROPHYJanuary 2020May 2024Abandon5121YesNo
16632472METHOD OF DIFFERENTIATION OF HUMAN INDUCED PLURIPOTENT STEM CELL TO DERMAL PAPILLA PRECURSOR CELL AND USE THEREOFJanuary 2020January 2023Allow3621YesNo
16744095CELL REPOPULATED COLLAGEN MATRIX FOR SOFT TISSUE REPAIR AND REGENERATIONJanuary 2020September 2021Allow2010YesNo
16630498SELF-ASSEMBLED HYBRID HYDROGELS FORMED OF A SHORT AROMATIC PEPTIDE AND AN AROMATIC AMINO ACIDJanuary 2020June 2024Allow5331NoNo
16629792TISSUE MECHANICAL FRAGMENTATION DEVICE INTENDED FOR THE PREPARATION OF A COMPOSITION OF ISOLATED CELLS, AND CORRESPONDING METHODJanuary 2020January 2024Abandon4801NoNo
16713889METHODS OF USING CURVATURE-DEFINED SURFACES WITH VARYING CURVATURES TO DIRECT CELL ATTACHMENT, SPREADING, AND MIGRATIONDecember 2019October 2022Abandon3421YesNo
16713756CURVATURE-DEFINED CONVEX AND CONCAVE GEL SURFACES FOR USE IN CELL AND TISSUE CULTURING AND IN OTHER SURFACE AND INTERFACE APPLICATIONSDecember 2019October 2022Allow3411YesNo
16713644CURVATURE-DEFINED CONCAVE AND CONVEX PDMS SURFACES FOR USE IN CELL AND TISSUE CULTURING AND IN OTHER SURFACE AND INTERFACE APPLICATIONSDecember 2019March 2023Allow3910YesNo
16708725IMPLANTS, METHODS FOR MAKING IMPLANTS AND METHODS OF TREATING LIPOATROPHY DEFECTS THEREWITHDecember 2019April 2022Abandon2801NoNo
16708169Direct effect of extracted BMP on Mesenchymal Stem Cell Differentiation for use in a Culture Medium, Diagnostic Assay, and Adjunct or Stand-Alone Pharmaceutical TreatmentDecember 2019February 2025Abandon6041NoNo
16702245COMPOSITION FOR ANTIFREEZINGDecember 2019November 2023Allow4741NoNo
16617849DRIED TISSUE MODELNovember 2019February 2023Abandon3910NoNo
16692484METHOD FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELLSNovember 2019March 2022Allow2711YesNo
166130543D SUSPENSION METHOD FOR GENERATING AUTOLOGOUS MELANOCYTE BY INDUCING IPS CELLS AND APPLICATION THEREOFNovember 2019March 2023Abandon4021NoNo
16678873METHOD FOR PRODUCING MESENCHYMAL STEM CELL AND APPLICATION OF SAMENovember 2019January 2023Allow3821YesNo
16610971METHODS FOR CULTURING HUMAN KERATINOCYTESNovember 2019January 2023Allow3821NoNo
16610593METHOD FOR DECELLULARIZATION OF SKIN TISSUE, METHOD FOR CONSTRUCTION OF ARTIFICIAL SKIN, METHOD FOR PREPARATION OF HYDROGEL OF DECELLULARIZED SKIN TISSUE, LYOPHILIZED, DECELLULARIZED SKIN TISSUE, AND BIOINKNovember 2019September 2022Abandon3411YesNo
16609982TRANSCRIPTION FACTORS CONTROLLING DIFFERENTIATION OF STEM CELLSOctober 2019August 2023Abandon4611NoNo
166076653-DIMENSIONIAL (3D) TISSUE-ENGINEERED MUSCLE FOR TISSUE RESTORATIONOctober 2019April 2023Allow4221YesNo
16660003CARTILAGE REGENERATIVE MATERIALOctober 2019August 2021Allow2220YesNo
16596301PROGENITOR CELLS OF MESODERMAL LINEAGEOctober 2019July 2020Allow910NoNo
16593462CELL CULTIVATION METHOD, CELL SUPPORT COMPOSITE PRODUCTION METHOD, CULTIVATED CELLS, AND CELL SUPPORT COMPOSITEOctober 2019January 2024Allow5141YesNo
16593785XENOTRANSPLANTATION PRODUCTS AND METHODSOctober 2019August 2020Allow1101YesNo
16603162ISOLATION OF CELLS FROM HATCHED REPTILE EGGS FOR USE IN PRODUCTION OF BIOARTIFICIAL SKIN AND LEATHEROctober 2019December 2022Allow3911NoNo
16603082SYSTEM AND METHOD FOR SEEDING AND CULTURINGOctober 2019November 2020Allow1300NoNo
16583895NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLESSeptember 2019November 2022Allow3801YesNo
16573126METHOD OF MANUFACTURING CELL STRUCTURESeptember 2019September 2022Abandon3620YesNo
16494407CARTILAGE PRESERVATION MEDIASeptember 2019September 2023Abandon4831NoNo
16554257Low-macrophage-adhesion/activation culture devices and methods thereof for continuous hematopoiesis and expansion of hematopoietic stem cellsAugust 2019November 2023Abandon5121NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PYLA, EVELYN Y.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
12
Examiner Affirmed
6
(50.0%)
Examiner Reversed
6
(50.0%)
Reversal Percentile
69.2%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
29
Allowed After Appeal Filing
9
(31.0%)
Not Allowed After Appeal Filing
20
(69.0%)
Filing Benefit Percentile
44.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 31.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PYLA, EVELYN Y - Prosecution Strategy Guide

Executive Summary

Examiner PYLA, EVELYN Y works in Art Unit 1633 and has examined 266 patent applications in our dataset. With an allowance rate of 65.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner PYLA, EVELYN Y's allowance rate of 65.4% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PYLA, EVELYN Y receive 2.74 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PYLA, EVELYN Y is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +32.5% benefit to allowance rate for applications examined by PYLA, EVELYN Y. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 20.7% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 23.2% of cases where such amendments are filed. This entry rate is in the 22% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 18.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 24% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 22% percentile among all examiners. Of these withdrawals, 53.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 71.0% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 56% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.